Latest news with #TAEUS
Yahoo
5 days ago
- Business
- Yahoo
ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results
ANN ARBOR, Mich., August 14, 2025--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver system's probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and repeatability to its liver fat assessments. Initial testing of the new design on a small patient population demonstrated an order-of-magnitude improvement in performance against the gold standard MRI-PDFF measurements. The Company is initiating validation testing of the redesigned probe in a short controlled study to confirm these anticipated performance gains. Focused strategy for TAEUS Liver De Novo submission. The Company further advanced its regulatory strategy regarding its planned De Novo filing for TAEUS Liver with the U.S. Food and Drug Administration (FDA). ENDRA intends to conduct a hypothesis-driven, statistically powered prospective multisite clinical trial enrolling approximately 250 subjects. The final trial design and sample size will be vetted with the FDA, which will assist in achieving the statistical power necessary for the De Novo submission and for publication of results in peer-reviewed journals. The Company expects that the results from the short controlled study will be used for the FDA meetings to confirm the endpoints and protocol. This regulatory alignment is intended to pave the way for the launch of ENDRA's pivotal study by year-end. Expanded the intellectual property portfolio to 85 issued patents globally. During the second quarter of 2025, ENDRA was issued one additional U.S. patent, which covers methods for tuning the thermoacoustic probe. ENDRA's broad intellectual property portfolio provides protection for the TAEUS system with its novel thermoacoustic technology and supports the exploration of licensing opportunities for indications beyond its core focus. Implemented cost reductions while advancing TAEUS development. ENDRA has taken decisive steps to strengthen its financial position over the past nine months. These cost reductions were initiated in the fourth quarter of 2024 and included a decrease in headcount and a streamlining of operations, particularly in general and administrative expenses. As a result, second quarter 2025 operating expenses decreased 42% to $1.2 million compared with $2.2 million in the prior-year period. "Our redesigned TAEUS probe represents a major advancement in our ability to non-invasively assess liver health. The early data are extremely encouraging, and our ongoing validation study is an important step toward aligning with the FDA and beginning our pivotal trial later this year," said Alexander Tokman, ENDRA's Chief Executive Officer. "Metabolic diseases—often symptomless until late stages—are the underlying cause of many chronic illnesses, including steatotic liver disease or SLD, which affects more than two billion people worldwide and over 100 million Americans. Due to the absence of practical diagnostic tools for frontline clinicians, SLD remains grossly underdiagnosed. With TAEUS, we aim to bring liver diagnostics into everyday care and enable earlier detection, better treatment decisions and potentially reduce the enormous financial burden metabolic diseases place on the U.S. healthcare system." Second Quarter Financial Results During 2024, the Company implemented significant cost-reduction initiatives to strengthen its financial position while advancing its strategic priorities. In the second quarter of 2025, the Company's cash burn from operations was $1.1 million, nearly half the $2.1 million reported in the same quarter of 2024. Total operating expenses for the second quarter of 2025 were $1.3 million, down 42% year-over-year from $2.2 million, reflecting the impact of cost-optimization measures including streamlined staffing, reduced overhead and a leaner operating model. As a result, net loss for the second quarter of 2025 narrowed to $1.2 million from $2.2 million in the year-ago period. As of June 30, 2025, ENDRA reported $1.8 million in cash and cash equivalents, providing resources to execute its near-term operational and regulatory milestones. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit Forward-Looking Statements All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as "approximate," "anticipate," "attempt," "believe," "could," "estimate," "expect," "forecast," "future," "goal," "hope," "intend," "may," "plan," "possible," "potential," "project," "seek," "should," "will," "would," or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and De Novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA's ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA's ability to maintain compliance with Nasdaq listing standards and remain listed on a securities exchange; ENDRA's dependence on its senior management team; market acceptance of ENDRA's technology and the amount and nature of competition in its industry; ENDRA's ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law. [Financial Tables Follow] ENDRA Life Sciences Inc. Condensed Consolidated Balance Sheets Assets June 30, 2025 December 31, 2024 Current Assets (Unaudited) Cash $ 1,808,574 $ 3,229,480 Prepaid expenses 44,310 204,185 Total Current Assets 1,852,884 3,433,665 Non-Current Assets Fixed assets, net 63,419 69,281 Right of use assets 519,966 578,013 Prepaid expenses, long term 365,417 365,417 Other assets 5,986 5,986 Total Assets $ 2,807,672 $ 4,452,362 Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued liabilities $ 448,419 $ 508,293 Lease liabilities, current portion 128,218 96,937 Total Current Liabilities 576,637 605,230 Long Term Debt Lease liabilities 429,274 487,482 Warrant Liability 328,610 799,284 Total Long Term Debt 757,884 1,286,766 Total Liabilities 1,334,521 1,891,996 Stockholders' Equity Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17,488 and 17,488 shares issued and outstanding, respectively - - Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding - - Common stock, $0.0001 par value; 20,000,000 shares authorized; 752,390 and 536,908 shares issued and outstanding, respectively 74 53 Additional paid in capital 107,173,418 105,998,412 Stock payable - - Accumulated deficit (105,700,341 ) (103,438,099 ) Total Stockholders' Equity 1,473,151 2,560,366 Total Liabilities and Stockholders' Equity $ 2,807,672 $ 4,452,362 ENDRA Life Sciences Inc. Condensed Consolidated Statement of Operations (Unaudited) Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2025 2024 2025 2024 Operating Expenses Research and development $ 381,061 $ 716,366 $ 909,746 $ 1,757,892 Sales and marketing 68,834 162,952 137,825 401,612 General and administrative 851,195 1,351,535 1,722,801 2,851,890 Total operating expenses 1,301,090 2,230,853 2,770,372 5,011,394 Operating loss (1,301,090 ) (2,230,853 ) (2,770,372 ) (5,011,394 ) Other Income (Expenses) Other income (expense) 13,066 1,700 37,456 6,541 Warrant expense - - - Changes in fair value of warrant liability 62,112 - 470,674 - Gain or Loss on settlement of warrant exercise - - - Total other expenses 75,178 1,700 508,130 6,541 Loss from operations before income taxes (1,225,912 ) (2,229,153 ) (2,262,242 ) (5,004,853 ) Provision for income taxes - - - - Net Loss $ (1,225,912 ) $ (2,229,153 ) $ (2,262,242 ) $ (5,004,853 ) Net loss per share – basic and diluted $ (1.71 ) $ (0.08 ) $ (3.55 ) $ (0.26 ) Weighted average common shares – basic and diluted 717,107 15,590 637,362 10,857 View source version on Contacts Company Contact: Investor relationsinvestors@ Investor Relations Contact: Yvonne BriggsAlliance Advisors IR(310) 691-7100ybriggs@ 登入存取你的投資組合
Business Wire
15-05-2025
- Business
- Business Wire
ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results
BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of T hermo- A coustic E nhanced U ltra S ound (TAEUS ®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform the way steatotic liver disease (SLD) is diagnosed and managed, ENDRA is developing a revolutionary, low-cost, point-of-care diagnostic device—essentially a 'blood pressure cuff' for the liver. This strategic shift is aimed squarely at a massive and urgent healthcare challenge. Metabolic conditions, often undiagnosed until complications arise, are the root cause of a wide spectrum of chronic illnesses including SLD, which afflicts over 2 billion people worldwide and more than 100 million Americans. Often silent in its early stages, SLD is notoriously underdiagnosed due to the lack of practical tools for frontline clinicians. ENDRA is addressing this diagnostic gap with its proprietary TAEUS system, designed to make liver fat detection as routine and accessible as measuring blood pressure. "Obesity, type 2 diabetes and other metabolic diseases are among the most pressing health challenges today, adding in excess of $800 billion annually to U.S. healthcare costs," said Alexander Tokman, ENDRA's CEO. "Our TAEUS technology has the potential to shift the paradigm—providing earlier detection, broader access and enabling more personalized management of disease through accurate and inexpensive assessment of liver fat, which is a key early biomarker for various metabolic conditions and risk factors." A Targeted, Multi-Market Strategy to Maximize Impact Under its new go-to-market strategy, ENDRA has identified four key customer segments that are best positioned to deliver high-value care using TAEUS: Pharmaceutical companies and clinical research organizations: For efficient patient screening and monitoring in GLP-1 and related metabolic drug trials. Concierge medical practices: For comprehensive metabolic assessments and therapy monitoring in high-risk patients. Bariatric, metabolic and endocrinology clinics: To manage patients with obesity and diabetes, identify metabolic disorders and track therapeutic responses. Primary care and internal medicine providers: In this setting where most patients on GLP-1 therapies will be managed, scalable tools like TAEUS can have the greatest impact. A Smarter, Scalable TAEUS System In parallel, ENDRA is redesigning the TAEUS Liver system to enhance usability, performance and affordability. The next-generation device is expected to incorporate: AI-powered enhancements to boost diagnostic accuracy. Full integration of thermoacoustic and ultrasound technologies to streamline clinical workflow and reduce scan time. A compact, ergonomic design with lower manufacturing costs, optimized for scalability and broad clinical adoption—especially in primary care. Revised Regulatory Strategy for De Novo Submission for TAEUS Liver Device The company has made several significant changes to its regulatory strategy regarding the approach to its planned De Novo filing with the U.S. Food and Drug Administration (FDA). ENDRA intends to conduct a hypothesis-driven, statistically powered prospective clinical trial, as opposed to prior plans to use retrospective data based on a limited subject population. This pivotal trial is expected to be a multicenter study enrolling approximately 250 subjects. Currently, ENDRA is conducting a multisite pilot study to assess the liver fat measurement capabilities of TAEUS Liver against the gold standard MRI-PDFF. To date, these sites have acquired TAEUS scan data from over 100 subjects, which are being assessed against the corresponding MRI-PDFF results. The additional data provide important feedback to optimize product design for accuracy and repeatability, as well as to inform the pivotal clinical trial design to position TAEUS Liver for a successful De Novo submission. Subscription-Based Access to Accelerate Adoption To remove barriers to adoption and accelerate market penetration, ENDRA plans to offer TAEUS Liver through a monthly subscription model, thereby eliminating the need for upfront capital investments. This customer-friendly approach will be supported by a focused small direct sales team and bolstered by compelling clinical data from current and future clinical evaluation sites. Beyond the Liver: Expanding the Power of Thermoacoustics Looking further ahead, ENDRA plans to expand the utility of its patented TAEUS platform beyond liver fat measurement. Future applications include temperature monitoring during ablation therapies, as well as vascular and tissue perfusion imaging, thereby broadening the clinical impact of thermoacoustic technology across multiple specialties. During the first quarter, ENDRA was issued two new patents in China, bringing the total number of patents in its intellectual property portfolio to 84. The first patent relates to the adjustment of device settings for optimizing the acquisition of thermoacoustic measurements, while the second patent is part of a family of Internet-of-Things (IoT) patents targeting remote service applications. First Quarter Financial Results Driving Operational Efficiency with a Sharp Reduction in Cash Burn ENDRA has significantly tightened its cost structure to preserve capital as it advances key strategic initiatives. The company's cash burn for the first quarter of 2025 was $1.2 million, representing a substantial improvement from $1.7 million for the first quarter of 2024. Total operating expenses for the first quarter of 2025 were $1.5 million, a significant decrease compared with $2.8 million for the same period last year. This nearly 50% decrease reflects the impact of aggressive cost-cutting measures initiated in the second half of 2024, including streamlined staffing and a leaner operating model. Net loss for the first quarter of 2025 was $1.0 million compared with $2.8 million in the year-ago period. As of March 31, 2025, ENDRA had $2.1 million in cash and cash equivalents. Subsequent to quarter-end, ENDRA raised $0.8 million under its 2024 At-the-Market (ATM) facility and, as of April 30, 2025, had $2.5 million in cash and cash equivalents. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS ®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS ® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit Forward-Looking Statements All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as 'approximate,' "anticipate," 'attempt,' "believe," "could," "estimate," "expect," 'forecast,' 'future,' "goal," 'hope,' "intend," "may," "plan," 'possible,' 'potential,' 'project,' "seek," "should," "will," 'would,' or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and De Novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA's ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA's ability to maintain compliance with Nasdaq listing standards and remain listed on a securities exchange; ENDRA's dependence on its senior management team; market acceptance of ENDRA's technology and the amount and nature of competition in its industry; ENDRA's ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law. [Financial Tables Follow]
Associated Press
31-03-2025
- Business
- Associated Press
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of T hermo- A coustic E nhanced U ltraSound (TAEUS ® ), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Company's technical capabilities and go-to-market strategy for TAEUS Liver and determined that this new target market opportunity is far larger and more viable than its prior focus on hepatology and radiology markets, noting that metabolic diseases are an upstream phenomenon that lead to multiple risk factors including those specific to liver diseases. With this pivot toward metabolic health, ENDRA's revised mission is to develop and market an accurate, simple-to-use, inexpensive, point-of-care test – essentially a 'blood pressure cuff' – for the assessment and management of steatotic liver disease (SLD). 'SLD is on the rise and represents an enormous health burden that affects over two billion people globally and approximately one-third of the U.S. population. As GLP-1 therapies continue to be embraced to treat metabolic risk factors such as obesity, type 2 diabetes and cardiovascular disease, there is an unmet need for a cost-effective, simple-to-use and accurate point-of-care test,' said Alexander Tokman, Chief Executive Officer of ENDRA. 'We believe our TAEUS technology is uniquely positioned to fill this gap and meet the needs of providers, patients and payers. Our development efforts are now focused on refining TAEUS' design for this use as we continue to collect crucial clinical data to support our future De Novo regulatory filing with the FDA.' Highlights of this strategy include new target customer segments, enhanced TAEUS features to improve its adoption and a realignment of the business model, as described below: Identified new target customer segments. As part of the revised market strategy, TAEUS Liver will target four markets: Pharmaceutical companies and clinical research organizations to assist in the efficient screening and monitoring of subjects for GLP-1 and related clinical trials; Concierge medical practices to assist in screening patients for obesity, diabetes, cardiovascular risk factors and liver disease, as well as monitoring responses to lifestyle changes and drug therapies; Bariatric and metabolic clinics for managing obesity, detecting metabolic disorders and monitoring responses to therapies; and Primary care and internal medicine practices to screen patients for metabolic diseases related to obesity, diabetes and hypertension, as well as cardiovascular risk factors, and to monitor responses to lifestyle changes and drug therapies. The Company anticipates that patients prescribed GLP-1 therapies will be managed primarily by these providers, rather than hepatologists. Redefined and redesigning TAEUS Liver device to improve its scalability and adoption into new target markets. In order to meet market requirements as a biomarker solution, ENDRA will further TAEUS' development to be more accurate, simpler to use and more ergonomic, as well as scalable and more cost effective. As a result, ENDRA's management has developed a multi-generational product plan to include 1) new artificial intelligence features to improve accuracy, 2) full integration of thermo-acoustic and ultrasound technologies in a single device to simplify clinical workflow and reduce procedural time, and 3) a reduction in the device's form factor and a decrease in manufacturing cost. All of these changes are deemed necessary for greater adoption of TAEUS Liver in the new target markets, and particularly in the very large primary care market segment. Introducing a subscription-based sales model. Once commercially available, ENDRA expects to offer TAEUS through a monthly subscription-based sales model with no upfront capital expenditures to reduce the barrier to entry and maximize customer uptake. ENDRA intends to deploy a small direct sales force that will leverage TAEUS' value proposition as evidenced by clinical results from current and additional evaluation sites. Extend TAEUS applicability beyond liver health. To increase the value and versatility of TAEUS' patented thermoacoustic technology, ENDRA will develop several additional high-value applications, following the development and commercialization of TAEUS for its initial indication to measure liver fat. These expanded applications include temperature monitoring for ablation therapies, vascular and tissue perfusion. SLD is often asymptomatic and not easily detectable at the early stages, and represents a global health crisis affecting over two billion people worldwide including more than 100 million in the U.S. Despite its prevalence and severe health implications, there remains a significant gap in dependable, affordable and easily accessible point-of-care tools to accurately detect and monitor liver fat. As the number of people with SLD continues to rise, its impact on public health and healthcare systems is becoming more evident, particularly as it is strongly linked to metabolic syndrome and a range of chronic conditions such as obesity, type 2 diabetes, cardiovascular disease and even liver cancer. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS ® ), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS ® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit Forward-Looking Statements All statements in this press release that are not based on historical fact are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as 'approximate,' 'anticipate,' 'attempt,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'hope,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'project,' 'seek,' 'should,' 'will,' 'would,' or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and De Novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA's ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA's ability to maintain compliance with Nasdaq listing standards and remain listed on a securities exchange; ENDRA's dependence on its senior management team; market acceptance of ENDRA's technology and the amount and nature of competition in its industry; ENDRA's ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law. Investor relations [email protected] Relations Contact: Yvonne Briggs Alliance Advisors IR (310) 691-7100 KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN INDUSTRY KEYWORD: TECHNOLOGY FDA DIABETES HEALTH PHARMACEUTICAL ARTIFICIAL INTELLIGENCE OTHER TECHNOLOGY RESEARCH MEDICAL DEVICES MANAGED CARE HEALTH TECHNOLOGY SCIENCE CLINICAL TRIALS CARDIOLOGY SOURCE: ENDRA Life Sciences Inc. Copyright Business Wire 2025. PUB: 03/31/2025 08:05 AM/DISC: 03/31/2025 08:06 AM
